Lindbrook Capital, LLC Dyne Therapeutics, Inc. Transaction History
Lindbrook Capital, LLC
- $1.18 Billion
- Q3 2024
A detailed history of Lindbrook Capital, LLC transactions in Dyne Therapeutics, Inc. stock. As of the latest transaction made, Lindbrook Capital, LLC holds 324 shares of DYN stock, worth $7,772. This represents 0.0% of its overall portfolio holdings.
Number of Shares
324
Previous 324
-0.0%
Holding current value
$7,772
Previous $11,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding DYN
# of Institutions
209Shares Held
102MCall Options Held
234KPut Options Held
238K-
Atlas Venture Life Science Advisors, LLC8.02MShares$192 Million35.54% of portfolio
-
Black Rock Inc. New York, NY7.39MShares$177 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.86MShares$165 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY6.82MShares$164 Million3.9% of portfolio
-
Janus Henderson Group PLC London, X06.81MShares$163 Million0.13% of portfolio
About Dyne Therapeutics, Inc.
- Ticker DYN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 51,765,400
- Market Cap $1.24B
- Description
- Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...